Cargando…

Risk of New Vertebral Fracture and Combination Therapy with Zoledronic Acid and Teriparatide in Diabetic Patients after Percutaneous Kyphoplasty

STUDY DESIGN: This was a retrospective clinical study. PURPOSE: This study aimed to evaluate the effect of combination therapy with zoledronic acid and teriparatide on the risk of new vertebral fracture (NVF) in type 2 diabetes mellitus (T2DM) patients after percutaneous kyphoplasty (PKP). OVERVIEW...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jian, Yan, Bin, Chen, Zhe, Zheng, Zhaomin, Yang, Changsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Spine Surgery 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561158/
https://www.ncbi.nlm.nih.gov/pubmed/33189105
http://dx.doi.org/10.31616/asj.2020.0282
_version_ 1784593072040968192
author Zhang, Jian
Yan, Bin
Chen, Zhe
Zheng, Zhaomin
Yang, Changsheng
author_facet Zhang, Jian
Yan, Bin
Chen, Zhe
Zheng, Zhaomin
Yang, Changsheng
author_sort Zhang, Jian
collection PubMed
description STUDY DESIGN: This was a retrospective clinical study. PURPOSE: This study aimed to evaluate the effect of combination therapy with zoledronic acid and teriparatide on the risk of new vertebral fracture (NVF) in type 2 diabetes mellitus (T2DM) patients after percutaneous kyphoplasty (PKP). OVERVIEW OF LITERATURE: Although T2DM had been associated with bone fragility and increased fracture risk, it remains unknown whether patients with T2DM could expect similar benefit from the combination therapy with zoledronic acid and teriparatide following PKP. METHODS: Total 106 diabetic patients who had undergone PKP and had received anti-osteoporosis treatment for osteoporotic vertebral compression fracture were enrolled and allocated into the following two groups: group I (n=52, zoledronic acid) and group II (n=54, zoledronic acid plus teriparatide). The operating time, bone cement volume, and complications related to anti-osteoporosis treatment or PKP, if any, were recorded. The Visual Analog Scale (VAS) score and Oswestry Disability Index (ODI) were assessed at admission, at discharge, and at the final follow-up. Dual-energy X-ray absorptiometry scan of the hip for the measurement of the bone mineral density (BMD) was performed preoperatively and at the final follow-up for all the patients. RESULTS: There was no significant difference in the age, body mass index, bone cement volume, or follow-up time of the groups. The mean follow-up duration was 22.5±1.6 months. All the patients had improved VAS and ODI, and group II had significantly better clinical outcomes than group I. All the patients had increased BMD at the latest follow-up, while group II exhibited significantly more improvement. The prevalence of NVF was lower in group II (11.5% vs. 7.4%, p=0.523). Male patients had a higher prevalence of NVF although the difference was not statistically significant. CONCLUSIONS: Combination therapy with zoledronic acid and teriparatide could improve the clinical outcomes, and BMD and had the potential to reduce NVF in diabetic patients following PKP.
format Online
Article
Text
id pubmed-8561158
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Korean Society of Spine Surgery
record_format MEDLINE/PubMed
spelling pubmed-85611582021-11-12 Risk of New Vertebral Fracture and Combination Therapy with Zoledronic Acid and Teriparatide in Diabetic Patients after Percutaneous Kyphoplasty Zhang, Jian Yan, Bin Chen, Zhe Zheng, Zhaomin Yang, Changsheng Asian Spine J Clinical Study STUDY DESIGN: This was a retrospective clinical study. PURPOSE: This study aimed to evaluate the effect of combination therapy with zoledronic acid and teriparatide on the risk of new vertebral fracture (NVF) in type 2 diabetes mellitus (T2DM) patients after percutaneous kyphoplasty (PKP). OVERVIEW OF LITERATURE: Although T2DM had been associated with bone fragility and increased fracture risk, it remains unknown whether patients with T2DM could expect similar benefit from the combination therapy with zoledronic acid and teriparatide following PKP. METHODS: Total 106 diabetic patients who had undergone PKP and had received anti-osteoporosis treatment for osteoporotic vertebral compression fracture were enrolled and allocated into the following two groups: group I (n=52, zoledronic acid) and group II (n=54, zoledronic acid plus teriparatide). The operating time, bone cement volume, and complications related to anti-osteoporosis treatment or PKP, if any, were recorded. The Visual Analog Scale (VAS) score and Oswestry Disability Index (ODI) were assessed at admission, at discharge, and at the final follow-up. Dual-energy X-ray absorptiometry scan of the hip for the measurement of the bone mineral density (BMD) was performed preoperatively and at the final follow-up for all the patients. RESULTS: There was no significant difference in the age, body mass index, bone cement volume, or follow-up time of the groups. The mean follow-up duration was 22.5±1.6 months. All the patients had improved VAS and ODI, and group II had significantly better clinical outcomes than group I. All the patients had increased BMD at the latest follow-up, while group II exhibited significantly more improvement. The prevalence of NVF was lower in group II (11.5% vs. 7.4%, p=0.523). Male patients had a higher prevalence of NVF although the difference was not statistically significant. CONCLUSIONS: Combination therapy with zoledronic acid and teriparatide could improve the clinical outcomes, and BMD and had the potential to reduce NVF in diabetic patients following PKP. Korean Society of Spine Surgery 2021-10 2020-11-16 /pmc/articles/PMC8561158/ /pubmed/33189105 http://dx.doi.org/10.31616/asj.2020.0282 Text en Copyright © 2021 by Korean Society of Spine Surgery https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Study
Zhang, Jian
Yan, Bin
Chen, Zhe
Zheng, Zhaomin
Yang, Changsheng
Risk of New Vertebral Fracture and Combination Therapy with Zoledronic Acid and Teriparatide in Diabetic Patients after Percutaneous Kyphoplasty
title Risk of New Vertebral Fracture and Combination Therapy with Zoledronic Acid and Teriparatide in Diabetic Patients after Percutaneous Kyphoplasty
title_full Risk of New Vertebral Fracture and Combination Therapy with Zoledronic Acid and Teriparatide in Diabetic Patients after Percutaneous Kyphoplasty
title_fullStr Risk of New Vertebral Fracture and Combination Therapy with Zoledronic Acid and Teriparatide in Diabetic Patients after Percutaneous Kyphoplasty
title_full_unstemmed Risk of New Vertebral Fracture and Combination Therapy with Zoledronic Acid and Teriparatide in Diabetic Patients after Percutaneous Kyphoplasty
title_short Risk of New Vertebral Fracture and Combination Therapy with Zoledronic Acid and Teriparatide in Diabetic Patients after Percutaneous Kyphoplasty
title_sort risk of new vertebral fracture and combination therapy with zoledronic acid and teriparatide in diabetic patients after percutaneous kyphoplasty
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561158/
https://www.ncbi.nlm.nih.gov/pubmed/33189105
http://dx.doi.org/10.31616/asj.2020.0282
work_keys_str_mv AT zhangjian riskofnewvertebralfractureandcombinationtherapywithzoledronicacidandteriparatideindiabeticpatientsafterpercutaneouskyphoplasty
AT yanbin riskofnewvertebralfractureandcombinationtherapywithzoledronicacidandteriparatideindiabeticpatientsafterpercutaneouskyphoplasty
AT chenzhe riskofnewvertebralfractureandcombinationtherapywithzoledronicacidandteriparatideindiabeticpatientsafterpercutaneouskyphoplasty
AT zhengzhaomin riskofnewvertebralfractureandcombinationtherapywithzoledronicacidandteriparatideindiabeticpatientsafterpercutaneouskyphoplasty
AT yangchangsheng riskofnewvertebralfractureandcombinationtherapywithzoledronicacidandteriparatideindiabeticpatientsafterpercutaneouskyphoplasty